Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Should You Buy?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) shares gapped up prior to trading on Tuesday . The stock had previously closed at $37.77, but opened at $40.00. Structure Therapeutics shares last traded at $39.4220, with a volume of 259,048 shares.

Wall Street Analysts Forecast Growth

GPCR has been the topic of several analyst reports. HC Wainwright decreased their target price on shares of Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, March 16th. Canaccord Genuity Group initiated coverage on shares of Structure Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating and a $101.00 target price on the stock. BMO Capital Markets set a $145.00 target price on shares of Structure Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. Wall Street Zen downgraded shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.25.

Structure Therapeutics Stock Performance

The stock’s 50-day simple moving average is $44.03 and its 200-day simple moving average is $57.13. The firm has a market capitalization of $2.84 billion, a PE ratio of -45.64 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. As a group, analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in GPCR. Geode Capital Management LLC increased its position in Structure Therapeutics by 18.5% during the 2nd quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock valued at $1,124,000 after purchasing an additional 8,444 shares during the period. Invesco Ltd. increased its position in Structure Therapeutics by 7.6% during the 2nd quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock valued at $8,805,000 after purchasing an additional 30,162 shares during the period. Marshall Wace LLP increased its position in Structure Therapeutics by 474.9% during the 2nd quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock valued at $3,651,000 after purchasing an additional 145,434 shares during the period. Jump Financial LLC grew its position in shares of Structure Therapeutics by 105.9% in the 2nd quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock worth $1,311,000 after buying an additional 32,524 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Structure Therapeutics in the 2nd quarter worth about $3,480,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.